🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

ALYSA LIU COOL GIRL WORLD CHAMPION GOAT EXTRAORDINAIRE

This one began with a nagging doubt. 🧵 We’ve all seen the rising enthusiasm for adding Abi to RT + ADT for high-risk prostate cancer, driven by STAMPEDE trial. But in the PSMA-PET era, is this systemic intensification always necessary? nature nature.com/articles/s4139…

What we found (over 65 months median f/u): ✅ 6-year MFS: 80.7% ✅ PCSS: 95.8% ✅ OS: 94.4% Similar to the STAMPEDE + abiraterone arm What this means? In patients staged with PSMA-PET and treated with Augmented WPRT RT, the incremental benefit of adding Abi may be modest

What this means? In patients staged with PSMA-PET and treated with Augmented/intensified WPRT RT, the incremental benefit of adding abiraterone may be modest We hope this adds nuance to personalising Rx for HR Ca Prostate—balancing benefit, cost, access, and toxicity.

👀 NEW Paper Systemic rx ⬆️ in PSMA-staged high risk prostate ca - is RT+ADT good enough?? Congrats Ashesh!👏🏼 OPEN ACCESS 👇 nature.com/articles/s4139… Builds on #ESTRO2025 debate ☢️ vs💊 for high risk prostate ca by Vedang Murthy Check out new trial RELAX on this Q! 🤩

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

🔬Cancer of Unknown Primary NEJM ✅Excellent review with diagnostic/management algorithm 👉nejm.org/doi/full/10.10… OncoAlert Gil Morgan, MD #cancer #oncology #MedX #ASCO25

This study reports on incredible results with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma. nejm.org/doi/full/10.10…

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

📢 #ASCO25: In pts w/ 5–20 brain mets, SRS/SRT led to fewer symptoms & less functional interference vs HA-WBRT, w/ similar OS (~8.4 mo). 🔬 Phase 3 RCT (n=196) 💡 SRS/SRT = new SoC for brain mets >4? meetings.asco.org/abstracts-pres… #RadOnc #NeuroOnc #SRS #WBRT #BrainMets

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

Ultimate review on Reirradiation. All that you need to know in one place. Must read!! doi.org/10.3322/caac.7… OncoAlert

First study I’m aware of that integrates PSMA & MRI to define DIL and then treats DIL, prostate and pelvis all in 5 SBRT treatments. Should we have called it Super-FLAME?

Dr. Andrew Loblaw Would like to introduce the HypoFocal trials using MRI and PSMA PET Phase II reached primary endpoint: linkinghub.elsevier.com/retrieve/pii/S… and sciencedirect.com/science/articl… Phase III ongoing with >200 patients recruited: mdpi.com/2072-6694/13/2…

How to select pts with HCC for various local therapies? RFA ,MWA , TACE , SIRT , SBRT . Useful for clinical decision-making. Taken from #asco25 ASCO Do u agree ? Yakup Ergün Dr. Nina Niu Sanford Jeff Ryckman OncoAlert Kate Sears

‼️ PACE-C RCT Prostate cancer -> 60 Gy/20 fx vs 36.25 Gy/5 fx Grade 2+ CTCAE GI toxicity: 10% vs 17% favoring 20 fx, p=0.0011 Grade 2+ CTCAE GU toxicity: 28% vs 34% favoring 20 fx, p=0.050 Why do a more toxic regimen with 5 fx? 👎 👎 👎

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR:

🎯 Less is more for prostate cancer radiotherapy! Mounting evidence💥 #prostatecancer ESTRO

🏃‍♂️💥 Exercise boosts immunotherapy! New study shows exercise increases gut microbiota-derived formate, enhancing CD8+ T cell–mediated antitumor immunity via Nrf2. ⭐️Formate may be a new biomarker for better ICI response in melanoma. Cell Press OncoAlert #microbiome #cancer